Medication abortion, a two-step process using mifepristone and misoprostol, constitutes over half of all US abortions and is increasingly vital due to abortion restrictions. Highly effective before ten weeks of pregnancy, mifepristone’s access has become fiercely contested since the overturning of Roe v. Wade. Recent legal challenges to the drug’s availability were dismissed by the Supreme Court due to the plaintiffs lacking legal standing. This ruling, however, does not guarantee continued nationwide access to the drug.
Read More
Judge Matthew Kacsmaryk ruled that Idaho, Kansas, and Missouri can proceed with a lawsuit aiming to restrict access to mifepristone. The states seek to limit telehealth prescriptions, shorten the gestational limit for use, and mandate in-person visits, arguing these measures are necessary to uphold state abortion laws. The ACLU criticized the decision, viewing it as an attack on medication abortion. This case follows a previous ruling by Kacsmaryk against mifepristone and comes amidst ongoing efforts by multiple states to further restrict access to abortion pills. The outcome could significantly impact abortion access nationwide.
Read More
The news of the surge in US abortions reaching the highest level in over a decade, sparked by a surge in medication abortion, doesn’t come as a shock to many. The statistics provided may not accurately represent the actual number of abortions taking place due to the stockpiling of abortion medication by women in anticipation of potential bans. As someone who values women’s reproductive rights, it is disheartening to see the manipulation of data and the restrictions imposed on access to healthcare options such as abortion.
It is evident that the true reduction of abortion rates lies in ensuring access to healthcare for all, especially for marginalized groups such as poor and rural women.… Continue reading
John Q. Hosedrinker